- This event has passed.
NGS 2016 Nordic
November 8, 2016 - November 9, 2016
The third annual NGS 2016 Nordic Conference took place at Medicon Village in Lund and was organised in partnership with the Kennedy Centre at Rigshospitalet, Odense University Hospital and Lund Cancer Centre.
The conference, which was opened by Prof Thoas Fioretos, focused on the use of Next Generation Sequencing (NGS) technologies and tools to look at human disease whether in a research or a clinical setting.
We covered the following areas: NGS Applications and workflows, Personalized Genomics, the Metagenomics link to health/disease, Non-invasive Prenatal testing, Cancer and Rare Disease genetics as well as Data Analysis and Storage.
NETWORKING: in addition to the excellent science, NGS 2016 Nordic allowed all delegates to interact with each other during networking events that included an introductory networking session, a panel debate and a networking dinner on the evening of 8th November.
Who attend the event:
- NGS users, researchers and students
- NHS & Private Labs, Biotech Companies, CRO’s, Service Providers
…and others interested in the latest developments of:
- Next Generation Sequencing
- Computational Biology
- Data Analysis
- Data interpretation
- DNA Sequencing
- Infectious and Inherited Diseases
- NGS Data Storage
- Molecular and Cell Biology
- Molecular Diagnostics
|09.00 – 10.30:||Registration, Coffee & Networking|
|10.30 – 11.00:||Dr Ed Quazi – Networking and Collaborations Workshop|
|11.00 – 11.30:||Prof Thoas Fioretos, Translational & Clinical Genomics, Lund University – Implementation of Next Generation Sequencing in Healthcare|
|11.30 – 12.00:||Prof Torben Kruse, Odense University Hospital – Genomic studies of tumour development: Heterogeneity and Metastasis|
|12.00 – 12.30:||TECHNOLOGY PRESENTATION by Dr John Wahlgren, Covaris – Active extraction of nucleic acids for NGS from challenging samples|
|12.30 – 13.30:||Lunch, Exhibition, Networking|
|13.30 – 14.00:||Prof Janna Saarela, Finnish Institute of Molecular Medicine – NGS in the diagnostics of rare immune diseases|
|14.00 – 14.30:||Dr Klaus Brusgaard, Odense University Hospital, Denmark – Exome sequencing in patients with undiagnosed congenital hyperinsulinism|
|14.30 – 15.00:||TECHNOLOGY PRESENTATION by Dr Tim Watts, Illumina – Needle in a Haystack: Using targeted panels to link Phenotype and Genotype|
|15.00 – 15.30:||Coffee, Exhibition & Networking|
|15.30 – 16.00:||Dr Asbjorg Stray-Pedensen, Oslo University Hospital – Clinical utility of NGS in syndrome diagnostics & newborn screening with a focus on primary deficiencies & congenital bone marrow|
|16.00 – 16.30:||Prof Anna Wedell, Medical Genetics, Karolinska Institute – Whole Genome Sequencing for rapid clinical diagnosis of inherited disorders|
|16.00 – 17.00:||Dr Alexandra Topa, Sahlgrenska University Hospital – The “clinical eye” is an essential tool for the interpretation of large amount of data from high throughput sequencing|
|17.00 – 18.00:||PANEL DEBATE – NGS bottlenecks: How do we cope with the ever increasing challenges?|
|18.00:||DRINKS RECEPTION SPONSORED BY WAFERGEN|
|19.00:||NETWORKING DINNER (booking required)|
|09.00 – 09.30:||Prof Mauno Vihinen, Department of Experimental Medical Science, Lund University – High precision tools to solve the bottleneck in NGS Data Analysis|
|09.30 – 10.00:||Prof Zeynep Tümer, Kennedy Centre (Department of Clinical Genetics), Copenhagen University Hospital, Rigshospitalet – Simple may be more complex than assumed|
|10.00 – 10.30:||TECHNOLOGY PRESENTATION by Dr Richard Dixon, Omicia – Accurate and rapid clinical Whole-Genome Sequence (WGS) interpretation with Omicia for the UK’s 100,000 Genome Project|
|10.30 – 11.00:||Coffee, Exhibition & Networking|
|11.00 – 11.30:||Dr Ida Vogel, Aarhus University Hospital – Using NGS to diagnose fetal disease|
|11.30 – 12.00:||Dr Morten Dunno, University Hospital Copenhagen – Clinical experience with AmpliSeq RDY Exome assay|
|12.00 – 12.30:||TECHNOLOGY PRESENTATION by Dr Jan Ziegler, Thermo Fisher Scientific – NGS solutions for clinical research and routine diagnostic applications in pathology|
|12.30 – 13.30:||Lunch, Exhibition & Networking|
|13.30 – 14.00:||Prof Helena Kääriäinen, National Institute for Health and Welfare Helsinki, Finland – Mission Impossible: Genetic Counselling for everybody|
|14.00 – 14.30:||Dr Anna Lindstrand, Karolinska Institutet – Next generation studies of structural genomic rearrangements|
|14.30 – 15.00:||TECHNOLOGY PRESENTATION by Dr Steve Glavas, 10x Genomics – Long Range Sequencing, Haplotyping, de novo Diploid Genomes, and Single Cell RNA-seq|
|15.00 – 15.30:||Coffee, Exhibition & Networking|
|15.30 – 16.00:||Dr Lars Feuk, Uppsala University – Transcriptome Sequencing in Schizophrenia|
|16.00 – 16.30:||Dr Rasmus Lykke Marvig, Copenhagen University Hospital – Genomics of microbial pathogens during long-term chronic infections|
Covaris is the recognized industry leader for DNA fragmentation and Adaptive Focused Acoustics (AFA®) has become the gold standard for shearing DNA and RNA in Next-Generation Sequencing applications. Without introducing GC bias or thermal-induced damage, users can precisely and accurately fragment DNA sophia-genetics RNA to the 100-1500bp range with the microTUBE™, 2-5kb range with the miniTUBE™, and 6-20kb range with the g-TUBE™.
Building on the superior capabilities of AFA, Covaris has developed truXTRAC™, which efficiently extracts nucleic acids from FFPE tissues. The highly simplified workflow ensures high yield extraction of nucleic acids and allows for the seamless integration into NGS and other molecular applications. By using AFA technology on Covaris instruments, scientists can achieve better amplificability of released nucleic acids in single and multi-sample formats. Additionally, the truChIP™ Chromatin Shearing Kits provide an optimized, flexible, and universal protocol for chromatin shearing on the high performance Focused-ultrasonicators, thus enabling the inclusion of truChIP Chromatin Shearing into any ChIP Protocol. The truXTRAC and truChIP kits bring the advantages of AFA and Focused-ultrasonication directly to the lab with increased sensitivity and reproducibility. With an installed base of more than 3,500 systems worldwide, the Covaris AFA process is extensively cited in peer-reviewed research articles on DNA fragmentation using all available NGS systems and is considered to be the gold standard for DNA shearing. Covaris Focused-ultrasonicators are recommended by all major sequencing platform providers, and are used by leading Genome Centers worldwide including: the Centre National de Génotypage (CNG), the Wellcome Trust Sanger Institute, the Broad Institute, and the Beijing Genomics Institute (BGI). For more information, please visit: www.covarisinc.com
Driving innovation: As a startup, Illumina aspired to transform human health. Our initial products enabled researchers to explore DNA at an entirely new scale, helping them create the first map of gene variations associated with health, disease, and drug response. Every breakthrough opened up a new world, and showed us how much further there is to go. Finding answers: While the rate of progress is accelerating exponentially, we are only beginning to understand the clinical significance of the genome. What causes a cancer cell to mutate? What is the origin of a puzzling disease? Is it possible to prevent the next outbreak? Or safeguard the world’s food supply? These are just a few of the challenges that inspire us to push the boundaries of our imagination. Making a difference now: Today we are a global leader in genomics – an industry at the intersection of biology and technology. At the most fundamental level, we enable our customers to read and understand genetic variations. We strive to make our solutions increasingly simple, more accessible, and always reliable. As a result, discoveries that were unimaginable even a few years ago are now becoming routine – and are making their way into patient treatment. Empowering a healthy future: We now have the ability to sequence at an unprecedented scale. Collectively, this will give us a much deeper understanding of genetics than ever before. We will begin to truly unlock the power of the genome. These advances will trigger a fundamental shift in healthcare and beyond. Medicine will continue to become more preventive and more precise. We will be healthier, longer. We have only just begun. For more information visit www.illumina.com
Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. Through our Thermo Scientific, Applied Biosystems and Invitrogen brands, we offer an unmatched combination of innovative technologies, purchasing convenience and support.
Omicia is advancing genomics to the clinic. Omicia enables any clinical testing lab to develop a comprehensive genomic testing service and provide high quality clinical interpretation at scale. Unlike systems that were developed for research studies, our Opal Clinical™ informatics, interpretation and reporting platform combines an automated variant annotation and prioritization engine with a rules-based variant classification system to significantly improve the accuracy and turnaround time of clinical reporting.
10x Genomics meets the critical need for long range, structural and cellular information, with an innovative system that transforms short-read sequencing technologies. Our Chromium™ System supports comprehensive genomics and high-throughput single cell transcriptomics. It enables researchers to discover previously inaccessible genomic information at unprecedented scale, including phased structural variants, phased single nucleotide variants, and dynamic gene expression of individual cells—while leveraging their existing sequencing systems and workflows.
Eppendorf is a leading life science company that develops and sells instruments, consumables and services for liquid handling, sample handling and cell handling in laboratories worldwide. Its product range includes pipettes and automated pipetting systems, dispensers, centrifuges, mixers, spectrometers and DNA amplification equipment as well as ultra-low temperature freezers, fermentors, bioreactors, CO2 incubators, shakers and cell manipulation systems. Consumables such as pipette tips, test tubes, microliter plates, and disposable bioreactors complement the range of highest-quality premium products. Eppendorf offers a broad range of high quality, smart consumables and precise instruments to perform all steps upstream of the sequencing itself: from sample generation and storage via sample preparation/purification, library preparation, and quantification to PCR amplification. Eppendorf products are most broadly used in academic and commercial research laboratories, e.g., in companies from the pharmaceutical and biotechnological as well as the chemical and food industries. They are also aimed at clinical and environmental analysis laboratories, forensics and at industrial laboratories performing process analysis, production and quality assurance. Eppendorf was founded in Hamburg, Germany in 1945 and has about 2,930 employees worldwide. The company has subsidiaries in 25 countries and is represented in all other markets by distributors. www.eppendorf.com
BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance cellular studies and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, optimize respiratory care and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 45,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. For more information on BD, please visit www.bd.com.
Diagenode Corporation is a global Epigenetic company and Diagnostics assay manufacturer based in Liège, Belgium and Denville, NJ, USA. Diagenode offers the most comprehensive range of Epigenetic products in the world, amongst its product portfolio are the famous Bioruptor® Shearing devices, Premium® and Blueprint® antibodies, IP-Star® automated workstations and many reagents. From Diagenode’s founding in 2003 in Liège as a local Biotechnology startup, the company has expanded rapidly. Diagenode has opened its US branch in 2006 and developed a distribution and partnering network across the entire world with strong anchorages in Japan and other Asia-Pacific countries. Diagenode has been profitable since its creation. The company planned to develop extensively its range of innovative products in both the Epigenetics and Infectious diseases markets. In October 2013, Diagenode’s headquarters have moved into a brand new facility near to the Univeristy of Liège’s campus.
The BioNordika Group was founded during 1986-1989. We currently employ around 40 people in the five offices in Sweden, Denmark, Norway, Estonia and Finland with the idea of being an “interface of science” between advance niche life science product/service suppliers and our customers in Nordics via a streamlined platform.OUR STATEMENT “SCIENCE WHERE YOU ARE” represents a unique combination of life science Premium Brands of products being stored, supported and marketed locally. Our wide offering of products and services focus in the areas of Cell & Molecular Biology, Immunology & Diagnostics, Instruments & Disposables and Custom Products & Projects. Main Suppliers include: New England Biolabs, Sage Science, Cell Signaling Technology, OriGene, Lonza
WaferGen Bio-systems, Inc. is a biotechnology company that offers innovative genomic technology solutions for single-cell analysis and clinical research. The ICELL8™ Single-Cell System is a first of its kind system that can isolate thousands of single cells and processes specific cells for analysis, including NGS. The system has demonstrated unbiased isolation of single cells from solid tumors, brain cells, pulmonary airway cells, and multiple cell lines. The SmartChip™ platform can be used for profiling and validating molecular biomarkers, and can perform massively-parallel singleplex PCR for one-step target enrichment and library preparation for clinical NGS. The Apollo 324™ system can be used to process DNA and RNA from clinical samples to NGS-ready libraries. These technologies offer a powerful set of tools for biological analysis at the molecular and single-cell level in the life sciences, pharmaceutical, and clinical laboratory industries. WaferGen recently announced a merger agreement with Takara Bio Inc. (TSE: 4974), a leading Japanese and global biotechnology and life science reagents company, which is expected to close in March of 2017.
Takara Bio Europe is a member of the Takara Bio Group, a leading supplier of tools for life scientists worldwide. Through our brand names TAKARA®, CLONTECH® and CELLARTIS™ we develop innovative technologies in the fields of Cell Biology, Molecular Biology, Proteomics and Stem Cell Research. From next-generation sequencing and PCR, to cloning and genomics, we offer high-performance reagents you can count on for all areas of molecular biology. Key products include SMARTer™ cDNA synthesis kits for Next Generation Sequencing, the innovative In-Fusion® HD Cloning Plus System, high performance PCR/qPCR reagents, Tet-regulated gene expression systems, Living Colors® Fluorescent Proteins, as well as a broad choice of viral vectors/particles and transduction tools. With the recent acquisition of Takara Bio Europe AB (formerly Cellartis), Takara Bio has expanded its portfolio with ready-to-use hiPSC derived hepatocytes and cardiomyocytes, culture media, as well as services such as iPS cell generation, engineering and differentiation. Our best-in-class products are backed by expert technical assistance, because good science needs great support.
Sophia Genetics was founded in 2011 to make Data Driven Medicine a reality. With the adoption of digital technologies, such as Next Generation DNA Sequencing, the healthcare industry entered the Big Data world raising new challenges in data protection and data analytics. We are today the only company in the field of genomics with both, ISO 13485 (medical device) and ISO 27001 (data security) certifications. With over 170 hospitals using our Sophia DDM® analytical platform, we have created the World’s Largest Clinical Genomics Community. Every week, we contribute in better diagnosing thousands of patients suffering from congenital disorders and cancer.
Triolab is a professional sales company founded in 1986. Triolab sells in vitro diagnostic equipment to the healthcare sector and we provide products and services for POC coagulation, hematology, microbiology, molecular diagnostics, clinical biochemistry, disease-specific analyzes, transfusion medical analyzes and for the preanalytical phase. Triolab represents many of the most successful European and American manufacturers of in vitro diagnostic. Most of our suppliers are ISO certified, and they deliver all products of recognized quality. In the field of molecular diagnostics, Triolab can offer both reagents, controls and instruments for diagnostic use and research. From different suppliers we can offer PCR kits and real-time PCR kits for the diagnostics of infectious and respiratory diseases, both as multiplex panels and singleplex. We have both low and high throughput instruments for real-time PCR and automated DNA purification. From leading suppliers Triolab offers different mutation analysis kits (B-RAF, K-Ras, BCR-ABL, ALK), as well as ELISA kits for the monitoring of anti-TNF-α. In the field of Next Generation Sequencing we offer kit for oncogenetics, humangenetics and kit for gene translocation analyses and gene clonality analyses for the detection of leukaemia and lymphoma for the most common NGS platforms.
PerkinElmer is focused on improving the health and safety of people and their environment. Our innovative and integrated detection, imaging, software, reagents and services solutions are accelerating discovery in core areas of research including genomics. From DNA to data, PerkinElmer understands your underlying science in every part of your workflow to help you analyse nucleic acids efficiently, at the lowest price per sample. Through our chemagen Technology platform PerkinElmer provides high-quality automated nucleic acid isolation research solutions incorporating highest sample volume flexibility and high throughput capability on just one instrument. Our innovative microfluidics technology delivers unparalleled electrophoresis separation for high-sensitivity DNA/RNA analysis, DNA smear analysis, and RNA and gDNA integrity analysis. Our next-generation sequencing library preparation workstations eliminate the processing bottlenecks presented by today’s sequencing technologies. Furthermore our genome analysis solutions suite leverages a proprietary, easy-to-use interface for interactive filtering and visualization to enhance data analysis from large genomic studies.
Nordic Biolabs AB. One of the leading distributors within Life Science in Scandinavia. We have a broad range of products for most of the applications within Cell culture, Proteomics, Biobanking and Molecular biology research. If you work on gene regulation, Epigenetics, NGS, PCR, DNA/RNA purification Cell culture, ….. and more! Don´t hesitate to contact our experienced Product Support Team backed up with the R&D from our suppliers for best technical support and advices in your daily research. We carefully select our suppliers and are proud to announce we carry products from well established suppliers as Active Motif, BD/Difco, Biocision, Biolegio, Biosan, Enzymatics, GE healthcare/Hyclone, Lexogen, Lucigen, Micronic, MP Biological, Ritter, Rubicon, Sartorius, Shield, Stratec Molecular, Thermo Fisher scientific/Pierce, TPP and Zymo. During this meeting we, together with Lucigen will focus on PCR-free library and happily answer your questions at our stand. Lucigen offers solutions to current problems in DNA cloning, sequencing, amplification, and protein expression by providing exceptionally reliable products and services to life science researchers in an ISO 13485 compliant environment. Lucigen is a leader in NGS library construction. Your next generation sequencing data is only as good as the library you create. Whether you need highly efficient DNA libraries for more uniform and deeper coverage or long span mate pair libraries to identify genome structural variation, gene/viral insertion sites or to create a scaffold for your de novo genome, the NxSeq® Technologies from Lucigen help you get there. Get more unique reads, deeper coverage, more complexity, and more efficiency from your fragment and mate pair library preps today. Lucigen also offers a wide range of NGS services to researchers looking to extract critical information from their human, animal, plant, or microbial genomes.
Kem-En-Tec was founded in 1987 by a team of Danish scientists from the Protein Laboratory at the University of Copenhagen. Kem-En-Tec Nordic is a strong and reliable partner and our success is based on reliability, high service level, flexibility and a high technological knowledge and support. We consider ourselves your service partner more than an “over the desk” supplier. Kem-En-Tec’s fundamental concept is to apply, offer and support the ideas and results of research & development by representing new and better quality products, ensuring improved results and more efficient use of resources for our customers. Our trained scientific staff isn’t hidden behind a call center, and we take pride in the fact that you will quickly receive a qualified reply – also if you choose to contact us by E-mail. Our services include extensive pre- as well as post selling support. Currently Kem-En-Tec repressent a platform of products from more than 100 companies in the field of Protein Technology, Molecular Biology, Cellularbiology, Diagnostics and Environmental studies.
Founded 1975 Techtum has provided laboratories with innovative instruments and consumables. Techtum is especially appreciated for its skilled staff, fast personal contacts, trusted support and service also after purchase. Our goal is to offer our customers innovative / smart / cost effective products to help in research and diagnostics. Our focus areas: Easy to use robots for NGS library preparation. True Digital PCR system – leading RainDrop platform for liquid biopsy and for creating more uniform NGS libraries. Smarter kits for NGS library preparation, cancer panels and cell freezing media etc. Accurate measuring concentrations of dsDNA/ssDNA/RNA/Proteins/cells – DropSense16/96. Safe sample storage for biobanks incl tubes, scanners, software and cappers/decappers.
LAST YEAR’S SPONSORS:
223 81 Lund
Tel: +46 46 275 60 00
HOW TO GET TO MEDICON VILLAGE
The Medicon Village is conveniently located close to Lund city centre and can be easily reached by bus from the central station. Bus route 1 and 6 run regularly (every 10 minutes) and the journey takes only 8 minutes. The closest stop to the Medicon Village is Lund Sparta which is only 200 m away from the entrance. More detailed information on buses and timetables can be found on this website: www.reseplanerare.resrobot.se
Alternatively the Medicon Village can also be reached by a short taxi ride from Lund Central Station (around 4 Km).
Whether you are travelling from the south or the north you’ll probably approach Lund from the E22 motorway. Take exit 22 (Lund Nord) into the E6 motorway and leave at the first exit. Turn left at the first roundabout and follow Scheelevägen for 1 km until you find the Medicon Village (n. 2) on your right hand side.
HOW TO GET TO LUND
COPENHAGEN AIRPORT is located around 50 Km from Lund. It’s directly connected to many international destinations and offers scheduled flights operated by most airlines including many low cost airlines. Copenhagen Airport is connected to Lund Central Station by regular direct trains: journey time is around 35 minutes and the price of a second class ticket is 137 SEK. The ticket office is located in Terminal 3 above the railway station. You can visit www.oresundstag.se to plan your journey.
MALMO AIRPORT: Malmö Airport is located 30 km from Malmö, and offers scheduled flights as well as charter flights to a number of destinations including various Eastern European cities. Flygbussarna Airport Coaches operates buses between the airport and Lund Central Station. The buses depart directly outside the airport terminal and travel time is around 40-50 minutes depending on the traffic. A return ticket costs around 200 SEK. More information can be found on the Flygbussarna website: www.flygbussarna.se
Lund has been on the main railway line between Malmö and Stockholm since 1857. Today there are direct connections to Copenhagen and Elsinore via the Oresund Bridge. This connections are mainly served by the Öresundståg. There are regular direct trains from:
Copenhagen Airport – 35 minutes journey
Copenhagen – 50 minutes journey
Malmo – 10 minutes journey
Gothenburg – 3 hours journey
Stockholm – just over 4 hours
Odense – there are no direct trains from Odense to Lund, but you can change in Copenhagen and total journey time will be less than 3 hours
You can visit www.oresundstag.se to plan your journey.
Lund can be easily reached by car and below you can find an indication of some of the distances:
Malmo – 20 Km
Copenhagen – 65 Km (road has toll)
Odense – 215 Km (road has toll)
Gothenburg – 260 Km
Aarhus – 240 Km (via ferry)